Global trends and hotspots of treatment for nonalcoholic fatty liver disease: A bibliometric and visualization analysis (2010-2023)

Table 1 Reported clinical results of neoadjuvant immunotherapy for resectable esophageal squamous cell carcinoma

Ref.	Year	Title	LCS	GCS
Musso et al[93]	2010	A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease	213	410
Sanyal et al[30]	2010	Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis	986	2063
Promrat et al[35]	2010	Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis	426	832
Ratziu et al[22]	2010	A position statement on NAFLD/NASH based on the EASL 2009 special conference	245	731
Lavine et al[94]	2011	Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the toninc randomized controlled trial	363	711
Musso et al[105]	2012	Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomised trials	224	435
Mudaliar et al[96]	2013	Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease	234	631
Neuschwander-Tetri et al[31]	2015	Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial	586	1416
Rinella et al[32]	2015	Nonalcoholic fatty liver disease: A systematic review	403	1443
Buzzetti et al[97]	2016	The multiple-hit pathogenesis of NAFLD	538	1386
Boursier et al[98]	2016	The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota	213	717
Cusi et al[106]	2016	Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: A randomized trial	277	525
Ratziu et al[107]	2016	Elafibranor, an agonist of the peroxisome proliferator-activated receptor-α and-δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening	350	642
Armstrong et al[36]	2016	Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): A multicentre, double-blind, randomised, placebo-controlled phase 2 study	529	1006
Friedman et al[37]	2018	Mechanisms of NAFLD development and therapeutic strategies	550	1526
Younossi et al[33]	2018	Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention	739	2379
Younossi[56]	2019	Non-alcoholic fatty liver disease-a global public health perspective	243	906
Younossi et al[6]	2019	Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis	254	808
Younossi et al[34]	2019	Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial	263	541

EASL: European association for the study of the liver; GCS: Global cited documents; LCS: Local cited documents; NAFLD: Nonalcoholic fatty liver disease; NASH: Nonalcoholic steatohepatitis.

Table 2 Top 25 references with strong citations

Rank	Ref.	Year	Primary research content	Strength	Beginning	Ending
1	Sanyal et al[30]	2010	Vitamin E showed improvement in nonalcoholic steatohepatitis in adults without diabetes	161.62	2010	2015
2	Chalasani et al[3]	2018	The diagnosis and management of nonalcoholic fatty liver disease practice guideline	150.14	2013	2017
3	Neuschwander-Tetri et al[31]	2015	Obeticholic acid improved the histological features of nonalcoholic steatohepatitis	102.84	2016	2020
4	Vernon et al[111]	2011	Systematic review: The epidemiology and natural history of NAFDL and NASH in adults	97.78	2012	2016
5	Chalasani et al[2]	2012	A practice guideline of the diagnosis and management of NAFLD	87.88	2013	2017
6	Williams et al[116]	2011	Prevalence of NAFLD was higher than estimated, especially in hispanics and diabetes patients	82.64	2012	2016
7	Promrat et al[35]	2010	Weight reduction achieved through lifestyle intervention led to improvements in liver histology in NASH	80.62	2011	2015
8	Vilar-Gomez et al[11]	2015	NASH resolution/fibrosis regression occurred in patients with ≥ 10% weight loss induced by lifestyle changes	77.63	2016	2020
9	Lavine et al[94]	2011	Neither vitamin E nor metformin was effective in reducing ALT in patients with pediatric NAFLD	76.39	2012	2016
10	Rinella et al[32]	2015	A systematic review of NAFLD	73.68	2016	2020
11	Cohen et al[101]	2011	NAFLD is strongly associated with obesity and insulin resistance	72.23	2012	2016
12	Angulo et al[110]	2015	Fibrosis stage was associated with long-term overall mortality, liver transplantation, and liver-related events	71.71	2016	2020
13	Ratziu et al[22]	2010	Collaboration between hepatologists and specialists in the endocrine, nutritional, and cardiology fields should be encouraged to optimize clinical management	62.53	2011	2015
14	Targher et al[7]	2010	NAFLD was associated with an increased risk of cardiovascular disease	58.16	2011	2015
15	Byrne et al[5]	2015	NAFLD is a multisystem disease, affecting extrahepatic organs and regulatory pathways	57.94	2016	2020
16	Ekstedt et al[108]	2015	Fibrosis stage predicted both overall and disease-specific mortality	57.38	2016	2020
17	Wong et al[109]	2015	NASH has been predicted to become the leading indication for liver transplantation	54.86	2016	2020
18	Anstee et al[112]	2013	NAFLD is associated with liver-related morbidity and mortality and an increased risk of developing cardiovascular disease and T2DM	50.86	2014	2018
19	Younossi et al[53]	2016	As the global epidemic of obesity fuels metabolic conditions, the clinical and economic burden of NAFLD will become enormous	125.36	2018	2021
20	Loomba et al[114]	2013	The epidemiology and demographic characteristics of NAFLD vary worldwide	63.19	2015	2018
21	Tilg et al[115]	2010	Many parallel hits derived from the gut and/or the adipose tissue may promote liver inflammation. endoplasmic reticulum stress and related signaling networks, (adipo) cytokines, and innate immunity are emerging as central pathways that regulate key features of NASH	58.39	2012	2015
22	Buzzetti et al[97]	2016	The multiple-hit pathogenesis of NAFLD	49.79	2018	2021
23	Eslam et al[102]	2020	A diagnosis of MAFLD requires positive criteria	75.68	2021	2023
24	Eslam et al[10]	2020	Renaming NAFLD to MAFLD was proposed to accelerate the translational path to new treatments	68.10	2021	2023
25	Newsome et al[103]	2021	Treatment with semaglutide resulted in a higher percentage of NASH resolution than placebo	55.16	2021	2023

ALT: Alanine aminotransferase; MAFLD: Metabolic dysfunction-associated fatty liver disease; NAFLD: Nonalcoholic fatty liver disease; NASH: Nonalcoholic steatohepatitis; T2DM: Type 2 diabetes mellitus.

Table 3 Top 20 high-frequency keywords (excluding the name of disease)

Rank	Keyword	Occurrence
1	Obesity	898
2	Insulin resistance	684
3	Inflammation	670
4	Metabolic syndrome	547
5	Oxidative stress	444
6	Steatosis	418
7	Fibrosis	414
8	Hepatocellular carcinoma	306
9	Lipid metabolism	304
10	Gut microbiota	260
11	Diabetes	258
12	Cirrhosis	241
13	Treatment	177
14	Autophagy	165
15	High-fat diet	141
16	Bariatric surgery	124
17	Cardiovascular disease	123
18	Metformin	121
19	Apoptosis	118
20	Lipogenesis	118